- £348.66m
- £412.00m
- £178.84m
- 84
- 51
- 94
- 93
Annual balance sheet for Alliance Pharma, fiscal year end - December 31st, GBP millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | R2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | — | — | — | — | — |
| Source: | ARS | ARS | ARS | ARS | ARS |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Cash | |||||
| Cash and Short Term Investments | 28.9 | 29.1 | 31.7 | 22.4 | 32.4 |
| Net Total Accounts Receivable | |||||
| Net Total Receivables | 24.2 | 27.7 | 48.2 | 51.7 | 46.3 |
| Total Inventory | |||||
| Prepaid Expenses | |||||
| Total Other Current Assets | |||||
| Total Current Assets | 77.2 | 81 | 105 | 104 | 104 |
| Gross Property, Plant And Equipment | |||||
| Accumulated Depreciation | |||||
| Net Property, Plant And Equipment | 15.9 | 4.83 | 5.58 | 5.72 | 5.44 |
| Net Goodwill | |||||
| Net Intangible Assets | |||||
| Other Long Term Assets | |||||
| Total Assets | 509 | 503 | 509 | 415 | 369 |
| Accounts Payable | |||||
| Accrued Expenses | |||||
| Notes Payable / Short Term Debt | |||||
| Current Portion of Long Term Debt / Capital Leases | |||||
| Total Other Current Liabilities | |||||
| Total Current Liabilities | 30.2 | 40.6 | 47 | 40.6 | 36.7 |
| Long Term Debt | |||||
| Capital Lease Obligations | |||||
| Total Long Term Debt | |||||
| Total Debt | |||||
| Deferred Income Tax | |||||
| Total Other Liabilities | |||||
| Total Liabilities | 228 | 221 | 244 | 197 | 161 |
| Common Stock | |||||
| Additional Paid In Capital | |||||
| Retained Earnings (Accumulated Deficit) | |||||
| Other Equity | |||||
| Total Equity | 281 | 282 | 266 | 218 | 208 |
| Total Liabilities & Shareholders' Equity | 509 | 503 | 509 | 415 | 369 |
| Total Common Shares Outstanding |